JAK
Les inhibiteurs de la kinase Janus (JAK) sont des composés qui ciblent la voie de signalisation JAK-STAT, impliquée dans la croissance cellulaire, la réponse immunitaire et l'angiogenèse. En inhibant JAK, ces composés peuvent réduire la signalisation qui conduit à la formation de nouveaux vaisseaux sanguins dans les tumeurs, inhibant ainsi la croissance tumorale. Les inhibiteurs de JAK sont importants dans le traitement des cancers et des maladies inflammatoires. Chez CymitQuimica, nous offrons une gamme diversifiée d'inhibiteurs de JAK de haute qualité pour soutenir vos recherches en oncologie, immunologie et angiogenèse.
245 produits trouvés pour "JAK"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
Tyrphostin AG 490
CAS :Formule :C17H14N2O3Degré de pureté :>98.0%(T)(HPLC)Couleur et forme :White to Light yellow powder to crystalMasse moléculaire :294.31Delgocitinib
CAS :<p>Delgocitinib is a potent JAK inhibitor (IC50: 2.8-58 nM), treats inflammatory diseases, and is the first topical drug for atopic dermatitis.</p>Formule :C16H18N6ODegré de pureté :99.95%Couleur et forme :SolidMasse moléculaire :310.35Gusacitinib
CAS :<p>Gusacitinib (ASN-002) (ASN-002) is spleen tyrosine kinase (SYK) and janus kinase (JAK) inhibitor (IC50: 5-46 nM).</p>Formule :C24H28N8O2Degré de pureté :98.06% - 99.94%Couleur et forme :SolidMasse moléculaire :460.53N-(3-Aminopropyl)cyclohexylamine
CAS :<p>N-(3-Aminopropyl)cyclohexylamine inhibits spermine synthase; used in neuro disease research.</p>Formule :C9H20N2Degré de pureté :98.05% - 98.82%Couleur et forme :Pale Yellow Clear LiquidMasse moléculaire :156.2685(E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide
CAS :Formule :C17H14N2O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :294.3047Golidocitinib
CAS :<p>Golidocitinib (AZD4205) is a selective JAK1 inhibitor (IC50: 73 nM) and weakly inhibits JAK2/JAK3 (IC50: >14.7, >30 μM).</p>Formule :C25H31N9O2Degré de pureté :98.87% - 99.88%Couleur et forme :SolidMasse moléculaire :489.57Ilginatinib maleate
CAS :<p>Ilginatinib maleate (NS-018 maleate) is a highly active and orally bioavailable inhibitor of JAK2.</p>Formule :C25H24FN7O4Degré de pureté :99.74% - 99.82%Couleur et forme :SolidMasse moléculaire :505.5WHI-P154
CAS :Formule :C16H14BrN3O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :376.2047Brepocitinib P-Tosylate
CAS :<p>Brepocitinib P-Tosylate (PF-06700841 P-Tosylate) is a potent dual inhibitor of Janus kinase 1 (JAK1) and TYK2 (IC50s of 17 nM and 23 nM, respectively).</p>Formule :C25H29F2N7O4SDegré de pureté :99.82% - 99.97%Couleur et forme :SolidMasse moléculaire :561.6WDR5-IN-6
CAS :<p>WDR5-IN-6 is a WDR5 inhibitor targeting the WBM locus.WDR5-IN-6 is highly synergistic with OICR-9429, a WDR5 inhibitor that targets the WIN locus.WDR5-IN-6</p>Formule :C13H8Cl2N2O2SDegré de pureté :99.69%Couleur et forme :SoildMasse moléculaire :327.19JAK2 Inhibitor V
CAS :<p>JAK2 Inhibitor V (JAK2 Inhibitor V Z3) is a novel specific inhibitor of Jak2, inhibiting Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner.</p>Formule :C23H24N2ODegré de pureté :98.36% - 99.15%Couleur et forme :SolidMasse moléculaire :344.45TAK-901
CAS :<p>TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others</p>Formule :C28H32N4O3SDegré de pureté :99.02% - 99.59%Couleur et forme :SolidMasse moléculaire :504.64Nimucitinib
CAS :<p>Nimucitinib is a Janus kinase (JAK) inhibitor that can be used to treat dry eye and promote tear production.</p>Formule :C25H26F2N6O2Degré de pureté :98.71%Couleur et forme :SoildMasse moléculaire :480.51Ilginatinib hydrochloride
CAS :<p>Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable inhibitor of JAK2.</p>Formule :C21H21ClFN7Degré de pureté :99.55%Couleur et forme :SolidMasse moléculaire :425.89Ilginatinib
CAS :<p>Ilginatinib (NS-018) is a highly active and orally bioavailable inhibitor of JAK2.</p>Formule :C21H20FN7Degré de pureté :98.4% - 99.01%Couleur et forme :SolidMasse moléculaire :389.43TYK2 activator-1
<p>TYK2activator-1 (16b) is a TYK2 activator with an EC50 value of 1.78 μM. It inhibits JAK2 and JAK3 with IC50 values of 6.8 μM and 6.3 μM, respectively.</p>Formule :C23H21FN4O2Couleur et forme :SolidMasse moléculaire :404.16485JAK-2/3-IN-1
CAS :<p>JAK-2/3-IN-1 inhibits JAK-2/3 isoforms with sub-250 nM Ki; from US patent US8163732B2.</p>Formule :C20H12ClN3OCouleur et forme :SolidMasse moléculaire :345.79Kinase Inhibitor Library
<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>Couleur et forme :Odour SolidLH168
<p>LH168 is a potent and selective probe for WDR5, with a SPR Kd value of 13 nM.</p>Formule :C29H31F3N6O2SCouleur et forme :SolidMasse moléculaire :584.66SJ1008030 formic
<p>SJ1008030 (compound 8) formic is a selective JAK2 degrader within the PROTAC class, demonstrating efficacy in inhibiting MHH-CALL-4 leukemia cell growth with an</p>Formule :C43H45N13O9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :919.96Deuruxolitinib
CAS :<p>Deuruxolitinib functions as an inhibitor of JAK1/2.</p>Formule :C17H18N6Couleur et forme :SolidMasse moléculaire :314.41JAK1/STAT3-IN-1
<p>JAK1/STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1/STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1/STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1/JAK1 and p-STAT3/STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).</p>Formule :C30H33FN4O3SCouleur et forme :SolidMasse moléculaire :548.67SJ988497
CAS :<p>SJ988497: PROTAC JAK2 degrader, inhibits CRLF2r cell growth, degrades GSPT1, combines Ruxolitinib, linker, Pomalidomide; researched for ALL.</p>Formule :C36H36N10O5Couleur et forme :SolidMasse moléculaire :688.74JAK-STAT Compound Library
<p>A unique collection of 252 JAK/STAT signaling targeted compounds for high throughput and high content screening;</p>Couleur et forme :Odour SolidTYD-68
<p>TYD-68 is a potent and selective CRBN-recruiting TYK2 PROTAC degrader, with a DC50 value of 0.42 nM. This compound effectively inhibits IL-12 and IFN-α-induced phosphorylation of STAT4 and STAT1, thereby blocking TYK2-dependent signaling pathways. TYD-68 is applicable in psoriasis research.</p>Couleur et forme :Odour SolidSJ10542
CAS :<p>SJ10542: potent JAK2/3-targeting PG-PROTAC; DC50s: JAK2 - 14 nM, JAK3 - 11 nM, JAK2-fusion ALL - 24 nM; CRBN recruiter.</p>Formule :C41H46N12O5SCouleur et forme :SolidMasse moléculaire :818.95JAK3-IN-15
<p>JAK3-IN-15 (compound 22) is a JAK3 inhibitor that reduces the secretion of p-JAK3 induced by LPS. It is utilized in research for rheumatoid arthritis.</p>Couleur et forme :Odour SolidJAK-IN-15
CAS :<p>JAK-IN-15 is a JAK inhibitor. WO2016119700A1 (Compound 15).</p>Formule :C22H23FN4O3SCouleur et forme :SolidMasse moléculaire :442.51Povorcitinib phosphate
CAS :<p>Povorcitinib phosphate is a selective JAK1 inhibitor and can be used in studies about the treatment of cutaneous lupus erythematosus and Lichen planus.</p>Formule :C23H25F5N7O5PDegré de pureté :99.57%Couleur et forme :SolidMasse moléculaire :605.45JAK1/TYK2-IN-1
CAS :<p>JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 and JAK1 ( IC 50 = 29 and 41 nM respectively).</p>Formule :C18H20F3N7OCouleur et forme :SolidMasse moléculaire :407.401JAK-IN-29
<p>JAK-IN-29 (Compound 3) is a potent inhibitor of Janus kinases (JAK) [1].</p>Formule :C17H14ClN5O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :355.78HAT-SIL-TG-1&AT
<p>HAT-SIL-TG-1&AT: a hypoxia-activated JAK inhibitor that curbs HEL cell growth & STAT3/5 phosphorylation in tumors.</p>Formule :C60H69N17O11SCouleur et forme :SolidMasse moléculaire :1236.36JI069
CAS :<p>JI069 (WAY-354189) is a potent STAT3 inhibitor that inhibits gp130 signaling by inducing dissociation between gp130 and JAK1.</p>Formule :C15H12Cl2N2O4SDegré de pureté :98.01%Couleur et forme :SolidMasse moléculaire :387.24Axltide
CAS :<p>Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.</p>Formule :C63H107N19O20S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1514.77JAK-IN-33
<p>JAK-IN-33 (Compound 3 (R)) is a selective inhibitor of the Janus kinase (JAK) family [1].</p>Degré de pureté :98%Couleur et forme :Odour SolidWDR5 ligand 2
CAS :<p>WDR5ligand 2 is a ligand for WDR5 and can be utilized in the synthesis of PROTAC WDR5degrader 1.</p>Formule :C29H31F3N4O4Couleur et forme :SolidMasse moléculaire :556.576JAK2-IN-10
CAS :<p>JAK2-IN-10 (compound 5) is a potent inhibitor of JAK2v617f, with an IC50 value of ≤10 nM.</p>Formule :C33H33D3FN9O2Couleur et forme :SolidMasse moléculaire :612.71DBL-6-13
<p>DBL-6-13 is an inhibitor of WDR5, displaying moderate binding affinity with dissociation constants (Kd) of 6.8 μM and 9.1 μM as determined by microscale thermophoresis analysis and fluorescence polarization analysis, respectively.</p>Formule :C25H38N4O3Couleur et forme :SolidMasse moléculaire :442.59JAK2-IN-6
CAS :<p>JAK2-IN-6: A potent JAK2-specific inhibitor (IC50=22.86μg/mL), blocks JAK2 signaling, has anticancer properties, and is inactive against JAK1/3.</p>Formule :C14H10ClN3OS2Degré de pureté :99.64%Couleur et forme :SolidMasse moléculaire :335.83Tyrosine Kinase Inhibitor Library
<p>A unique collection of 1016 tyrosine kinase inhibitors for high throughput screening and high content screening for drug discovery in tyrosine kinase related</p>Couleur et forme :Odour SolidTyk2-IN-22
CAS :<p>Tyk2-IN-22 (Compound A8) is a selective inhibitor of tyrosine kinase 2 (Tyk2), effectively inhibiting Tyk2, JAK1, and JAK3 with IC50 values of 9.7 nM, 148.6 nM, and 883.3 nM, respectively. Additionally, Tyk2-IN-22 suppresses downstream STAT5 phosphorylation.</p>Formule :C16H16ClN5O2Couleur et forme :SolidMasse moléculaire :345.78PROTAC TYK2 degradation agent1
CAS :<p>PROTAC TYK2 Agent1 selectively degrades TYK2, with a 14 nM DC50, for autoimmune research.</p>Formule :C55H69N13O7SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1056.28JAK/HDAC-IN-4
<p>JAK/HDAC-IN-4 (compound 11 i) is a dual inhibitor targeting both JAK2 and HDAC6, with IC50 values of 0.49 nM and 12 nM respectively. It inhibits cell proliferation and the production of nitric oxide. In a mouse model induced by Imiquimod, JAK/HDAC-IN-4 ameliorates psoriasiform skin lesions with low toxicity.</p>Formule :C30H32N8O5SCouleur et forme :SolidMasse moléculaire :616.69S-Ruxolitinib
CAS :<p>S-Ruxolitinib can be used in related research in the field of life sciences. Its product number is T3066 and CAS number is 1160597-27-2.</p>Formule :C17H18N6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :306.37AS2553627
CAS :<p>AS2553627 is a JAK inhibitor. AS2553627 prevents chronic rejection in rat cardiac allografts.</p>Formule :C18H19N5OCouleur et forme :SolidMasse moléculaire :321.38Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9)
CAS :<p>Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide derived from mouse JAK2, specifically composed of amino acids 475 to 491.</p>Formule :C88H138N20O34P2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :2082.1FDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Couleur et forme :LiquidSJ1008030
CAS :<p>SJ1008030, a JAK2 PROTAC, degrades JAK2; EC50: 5.4 nM, IC50: 32.09 nM in MHH-CALL-4 cells for leukemia research.</p>Formule :C42H43N13O7SCouleur et forme :SolidMasse moléculaire :873.94Pumecitinib
CAS :<p>Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib exhibits anti-inflammatory activity.</p>Formule :C17H20N8O2SDegré de pureté :99.94%Couleur et forme :SoildMasse moléculaire :400.46MR44397
<p>MR44397 is a ligand for WD40 repeat (WDR) 5 and is applicable in cancer research.</p>Formule :C23H26N4O2SCouleur et forme :SolidMasse moléculaire :422.54Ilunocitinib
CAS :<p>Ilunocitinib is a non-selective and orally active Janus kinase (JAK) inhibitor for pruritus and atopic dermatitis caused by atopic dermatitis in dogs.</p>Formule :C17H17N7O2SDegré de pureté :99.88%Couleur et forme :SolidMasse moléculaire :383.43Ifidancitinib
CAS :<p>Ifidancitinib (ATI-50002) is a JAK kinase 1/3 inhibitor used to study autoimmune diseases.</p>Formule :C20H18FN5O3Degré de pureté :98.05%Couleur et forme :SolidMasse moléculaire :395.39Atinvicitinib
CAS :<p>Atinvicitinib, a selective JAK1 inhibitor, blocks cytokine signaling, modulating itch, allergy, and inflammatory responses, immune and therapeutic studies.</p>Formule :C16H17FN6O3Degré de pureté :99.36%Couleur et forme :SolidMasse moléculaire :360.35CHZ868
CAS :<p>CHZ868 is a type II JAK inhibitor with potential antitumor activity that reverses the persistence of type I JAK inhibitors and can be used to study leukemia.</p>Formule :C22H19F2N5O2Degré de pureté :99.38%Couleur et forme :SolidMasse moléculaire :423.42WHI-P154
CAS :Formule :C16H14BrN3O3Degré de pureté :>98.0%(HPLC)Couleur et forme :White to Yellow to Orange powder to crystalMasse moléculaire :376.21Itacitinib adipate
CAS :<p>Itacitinib adipate: oral JAK1 inhibitor, tested in phase II myelofibrosis trial.</p>Formule :C32H33F4N9O5Couleur et forme :SolidMasse moléculaire :699.66WHI-P180 Hydrochloride
CAS :Formule :C16H15N3O3·HClDegré de pureté :>97.0%(T)(HPLC)Couleur et forme :White to Light gray to Light yellow powder to crystalMasse moléculaire :333.77DTP3
CAS :<p>DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.</p>Formule :C26H35N7O5Couleur et forme :SolidMasse moléculaire :525.6PF-06651600 malonate
CAS :<p>PF-06651600 is a potent and selective JAK3 inhibitor.</p>Formule :C18H23N5O5Couleur et forme :SolidMasse moléculaire :389.41Fedratinib hydrochloride hydrate
CAS :<p>Fedratinib hydrochloride hydrate (SAR 302503 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor.</p>Formule :C27H40Cl2N6O4SDegré de pureté :98.96% - 99.87%Couleur et forme :SolidMasse moléculaire :615.61AG490
CAS :<p>AG490 inhibits EGFR (0.1 μM IC50), 135x > selective than ErbB2, blocks JAK2, spares Lyn, Lck, Syk, Btk, Src.</p>Formule :C17H14N2O3Degré de pureté :98.6% - 99.39%Couleur et forme :Yellow SolidMasse moléculaire :294.3Abrocitinib
CAS :<p>Abrocitinib (PF-04965842) (PF-04965842) is a potent, specific and orally-active JAK1 inhibitor (IC50s: 29/803 nM for JAK1/2).</p>Formule :C14H21N5O2SDegré de pureté :99.09% - 99.91%Couleur et forme :SolidMasse moléculaire :323.41CEP-33779
CAS :<p>CEP-33779 is a novel and selective inhibitor of JAK2 with an IC50 of 1.8±0.6 nM.</p>Formule :C24H26N6O2SDegré de pureté :98.24% - ≥95%Couleur et forme :SolidMasse moléculaire :462.57SHR0302
CAS :<p>SHR0302 (ARQ252) is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3,</p>Formule :C18H22N8O2SDegré de pureté :99.11%Couleur et forme :SolidMasse moléculaire :414.48BD750
CAS :<p>BD750 is an effective immunosuppressant and a JAK3/STAT5 inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation(IC50 of 1.5 μM and 1.1 μM in</p>Formule :C14H13N3OSDegré de pureté :99.02%Couleur et forme :SolidMasse moléculaire :271.34Gandotinib
CAS :<p>LY2784544(Gandotinib (LY2784544)) is a potent JAK2 inhibitor (IC50: 3 nM), effective in JAK2V617F(Ki: 0.245 nM).</p>Formule :C23H25ClFN7ODegré de pureté :99.33% - 99.86%Couleur et forme :SolidMasse moléculaire :469.94Ritlecitinib tosylate
CAS :<p>Ritlecitinib (PF-06651600) is a potent, selective JAK3 inhibitor with proven in vivo efficacy, low clearance, and has undergone clinical trials.</p>Formule :C22H27N5O4SCouleur et forme :SolidMasse moléculaire :457.5492,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide
CAS :<p>2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide (GDC046), a potent lead analog, has good kinase selectivity and physicochemical properties.</p>Formule :C16H13Cl2N3O2Degré de pureté :98.77%Couleur et forme :SolidMasse moléculaire :350.2AT9283
CAS :<p>AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).</p>Formule :C19H23N7O2Degré de pureté :99.83% - 99.98%Couleur et forme :SolidMasse moléculaire :381.43Pacritinib hydrochloride
CAS :<p>Pacritinib HCl: strong JAK2/Wild-type & JAK2V617F inhibitor (IC50: 23/19 nM), used in AML & MF research.</p>Formule :C28H32N4O3·xClHCouleur et forme :SolidCurculigoside
CAS :<p>1.</p>Formule :C22H26O11Degré de pureté :99.85%Couleur et forme :SolidMasse moléculaire :466.44Tofacitinib Citrate
CAS :<p>Tofacitinib Citrate (CP-690550 citrate) is a a potent, cell-permeable inhibitor of JAK1/2/3 (IC50s: 1/20/112 nM).</p>Formule :C22H28N6O8Degré de pureté :99.19% - 99.75%Couleur et forme :SolidMasse moléculaire :504.49Ruxolitinib phosphate
CAS :<p>Ruxolitinib phosphate (INCB18424 phosphate) is a JAK1/2 inhibitor with IC50 of 3.3 nM/2.8 nM. Cost-effective and quality-assured.</p>Formule :C17H21N6O4PDegré de pureté :98% - >99.99%Couleur et forme :SolidMasse moléculaire :404.36GLPG0634 analog
CAS :<p>GLPG0634 analog (GLPG0634 analogue) is a specific JAK1 inhibitor with IC50 of 10/28/810/116 nM for JAK1/2/3 and TYK2, respectively.</p>Formule :C23H18N6O2Degré de pureté :99.52% - >99.99%Couleur et forme :SolidMasse moléculaire :410.43FLLL32
CAS :<p>FLLL32 is an effective JAK2/STAT3 inhibitor (IC50 of <5 μM).</p>Formule :C28H32O6Degré de pureté :97% - 97.90%Couleur et forme :SolidMasse moléculaire :464.55G5-7
CAS :<p>G5-7 is an oral JAK2 inhibitor targeting EGFR/STAT3 phosphorylation with potential for glioma research.</p>Formule :C22H19F2NO3Degré de pureté :97.3%Couleur et forme :SolidMasse moléculaire :383.39GDC-0214
CAS :<p>GDC-0214 is an inhaled small-molecule JAK1 inhibitor and reduces fractional exhaled nitric oxide (Feno).</p>Formule :C28H28ClF2N9O3Degré de pureté :99.75%Couleur et forme :SolidMasse moléculaire :612.03AMG-47a
CAS :<p>AMG-47a inhibits Lck, T cell growth, and degrades KRAS oncoprotein, affecting EGFP-KRASG12V but not EGFP.</p>Formule :C29H28F3N5O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :535.56AZ960
CAS :<p>AZ960 is an effective ATP competitive JAK2 inhibitor (IC50/Ki: <3 nM and0.45 nM).</p>Formule :C18H16F2N6Degré de pureté :96.02% - 98.51%Couleur et forme :SolidMasse moléculaire :354.36Decernotinib
CAS :<p>Decernotinib (VRT-831509)(VX-509; VRT-831509) is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays.</p>Formule :C18H19F3N6ODegré de pureté :99.28% - >99.99%Couleur et forme :SolidMasse moléculaire :392.38Baricitinib
CAS :<p>Baricitinib (INCB028050) is an orally JAK1 and JAK2 inhibitor. Baricitinib has anti-inflammatory and anti-tumor activity. Cost-effective and quality-assured.</p>Formule :C16H17N7O2SDegré de pureté :99% - >99.99%Couleur et forme :SolidMasse moléculaire :371.42JAK3-IN-6
CAS :<p>JAK3-IN-6 is irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC50 of 0.15 nM</p>Formule :C19H18N4O3Degré de pureté :99.94% - 99.94%Couleur et forme :SolidMasse moléculaire :350.37Ruxolitinib (S enantiomer)
CAS :<p>Ruxolitinib S enantiomer (INCB18424) is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective JAK1/2 inhibitor.</p>Formule :C17H18N6Degré de pureté :99.37% - 99.79%Couleur et forme :SolidMasse moléculaire :306.36WHI-P97 HCl
<p>WHI-P97 HCl is a potent and selective JAK-3 inhibitor.</p>Formule :C16H14Br2ClN3O3Degré de pureté :99.49%Couleur et forme :SolidMasse moléculaire :491.56Fedratinib
CAS :<p>Fedratinib (TG-101348) (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3.</p>Formule :C27H36N6O3SDegré de pureté :97.31% - 99.96%Couleur et forme :SolidMasse moléculaire :524.68RO495
CAS :<p>RO495 (CS-2667), a potent inhibitor of TYK2, inhibits TYK2 with IC50 of 1.5nM as tested in cell-based pharmacological assays</p>Formule :C17H14Cl2N6ODegré de pureté :97.94%Couleur et forme :SolidMasse moléculaire :389.24WP1066
CAS :<p>WP1066 is a inhibitor of JAK2 (IC50: 2.30 μM) and STAT3 (IC50: 2.43 μM) in HEL cells; shows activity to JAK2, STAT3/5, and ERK1/2, not JAK1 and JAK3.</p>Formule :C17H14BrN3ODegré de pureté :98.92% - 99.73%Couleur et forme :SolidMasse moléculaire :356.22Momelotinib HCl
CAS :<p>Momelotinib HCl is a JAK1/2 inhibitor, reducing anemia in myelofibrosis (MF) patients.</p>Formule :C23H24Cl2N6O2Couleur et forme :SolidMasse moléculaire :487.38RGB-286638 free base
CAS :<p>RGB-286638 free base inhibits CDKs (1-5 nM), weaker on CDK7/6.</p>Formule :C29H35N7O4Degré de pureté :98% - 99.91%Couleur et forme :SolidMasse moléculaire :545.63SC99
CAS :<p>SC99 inhibits JAK2-STAT3, reducing STAT3 genes, platelet activity, and has anti-myeloma, anti-thrombotic effects.</p>Formule :C15H8Cl2FN3ODegré de pureté :99.56%Couleur et forme :SolidMasse moléculaire :336.15Pyridone 6
CAS :<p>Pyridone 6, a selective JAK1/2/3 and Tyk2 inhibitor with IC50s: JAK1=15 nM, JAK2=1 nM, JAK3 (Ki=5 nM), Tyk2=1 nM; weakly binds other kinases (130 nM-10 μM).</p>Formule :C18H16FN3ODegré de pureté :97.1% - 98.74%Couleur et forme :SolidMasse moléculaire :309.34NVP-BSK805 trihydrochloride
CAS :<p>NVP-BSK805 trihydrochloride inhibits JAK2 (0.48 nM IC50); also affects JAK1, JAK3, TYK2.</p>Formule :C27H31Cl3F2N6OCouleur et forme :SolidMasse moléculaire :599.93Ritlecitinib
CAS :<p>Ritlecitinib (PF-06651600) is an orally available, selective JAK3 inhibitor and does not affect the activity of JAK1/2.Cost-effective and quality-assured.</p>Formule :C15H19N5ODegré de pureté :98.82% - 99.92%Couleur et forme :SolidMasse moléculaire :285.34(E/Z)-Zotiraciclib
CAS :<p>(E/Z)-Zotiraciclib ((E/Z)-TG02) inhibits CDK2, JAK2, and FLT3 effectively with IC50s of 13, 73, and 56 nM, respectively.</p>Formule :C23H24N4ODegré de pureté :97.75% - 99.92%Couleur et forme :SolidMasse moléculaire :372.46Deucravacitinib
CAS :<p>Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor.Cost-effective and quality-assured.</p>Formule :C20H19D3N8O3Degré de pureté :98.52% - >99.99%Couleur et forme :SolidMasse moléculaire :425.46WDR5-0103 hydrochloride[890190-22-4(free base)]
<p>WDR5-0103 hydrochloride[890190-22-4(free base)] (WD-Repeat Protein 5-0103) is an effective and specific WD repeat-containing protein 5 (WDR5) antagonist (Kd:</p>Formule :C21H26ClN3O4Degré de pureté :99.66%Couleur et forme :SolidMasse moléculaire :419.9XL019
CAS :<p>XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, 100 fold selectivity over JAK1.</p>Formule :C25H28N6O2Degré de pureté :99.19%Couleur et forme :SolidMasse moléculaire :444.53TG101209
CAS :<p>TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.</p>Formule :C26H35N7O2SDegré de pureté :99% - >99.99%Couleur et forme :SolidMasse moléculaire :509.67Brevilin A
CAS :<p>Brevilin A, a sesquiterpene from Centipeda minima, hinders JAK and blocks STAT3 (IC50=10.6μM), inducing apoptosis and autophagy in cancer cells.</p>Formule :C20H26O5Degré de pureté :99.97% - >99.99%Couleur et forme :SolidMasse moléculaire :346.42FM-381
CAS :<p>FM381, a JAK3 inhibitor with 127 pM IC50, is 410-3600x more selective over JAK1/2/TYK2.</p>Formule :C24H24N6O2Degré de pureté :98.44%Couleur et forme :SolidMasse moléculaire :428.49
![WDR5-0103 hydrochloride[890190-22-4(free base)]](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTM%2Fthumb-webp%2FT5140.webp&w=3840&q=75)
